Acupuncture Feasibility Trial for Dyspnea in Lung Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer, Pulmonary |
| Therapuetic Areas: | Oncology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/21/2016 |
| Start Date: | March 2014 |
This is a single arm clinical trial to establish the feasibility of conducting a clinical
trial of acupuncture in reducing dyspnea among lung cancer survivors who have completed
chemoradiotherapy. Twelve subjects with dyspnea will be recruited to this clinical trial. Up
to 10 sessions of acupuncture will be delivered over the course of 8-10 weeks. The primary
outcome will be dyspnea as measured by the English version of the Cancer Dyspnea Scale at
the completion of the intervention.
trial of acupuncture in reducing dyspnea among lung cancer survivors who have completed
chemoradiotherapy. Twelve subjects with dyspnea will be recruited to this clinical trial. Up
to 10 sessions of acupuncture will be delivered over the course of 8-10 weeks. The primary
outcome will be dyspnea as measured by the English version of the Cancer Dyspnea Scale at
the completion of the intervention.
Inclusion Criteria:
- Diagnosis of Lung Cancer (Non small cell and small cell both eligible)
- Completion of concurrent CRT at least 6 months prior to randomization.
- Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score
greater than or equal to 2 (Walks slower than people of the same age on the level
because of breathlessness or has to stop for breath when walking at own pace on
level)
- Ability to understand written English -Willingness to adhere to all study-related
procedures
- Age 18 years old
- ECOG Performance Status 1-3
Exclusion Criteria:
- Current receipt of therapy for treatment related pneumonitis for 3 weeks.
- Surgical resection of this LC (lobectomy or pneumonectomy)
- Another organic cause of dyspnea necessitating treatment (eg pleural effusion
appropriate for thoracentesis, rapidly progressive intrathoracic recurrence,
symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL)
- Current bleeding disorder by history
- Life expectancy of 12 weeks, as assessed by primary oncologist
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Principal Investigator: Josua Bauml, MD
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
